Patents Examined by Michael G. Wityshyn
  • Patent number: 5712131
    Abstract: This invention provides an improved process of recovering organic acid from an impure process stream, such as a fermentation broth, by the addition of a strong acid or salt thereof to the impure process stream. The process provides for essentially one step purification without the waste disposal problems or large capital investment required by either the conventional lime/sulfuric or solvent extraction recovery processes. The recovery can be further improved by treating the mother liquor remaining after separation of the citric acid crystals to obtain an additional yield. The preferred strong acid is sulfuric acid and the preferred mother liquor treatment is passage through an ion exclusion resin column.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 27, 1998
    Assignee: Bayer Corporation
    Inventors: Steven W. Felman, Chetna Patel, Bhalchandra H. Patwardhan, David J. Solow
  • Patent number: 5707657
    Abstract: A food supplement comprises isolated animal mesenchymal matter of fetal origin and extracts of animal organs of fetal origin, the mesenchymal matter consisting of a network of loose connective tissue and the food supplement being free of chemical preservatives.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: January 13, 1998
    Inventor: Raymond Bontemps
  • Patent number: 5702930
    Abstract: A microbiological process for the preparation of a heteroaromatic carboxylic acid or one of its physiologically tolerated salts of the formulae I or II: ##STR1## wherein R.sub.1 and R.sub.2 are identical or different and each denotes a hydrogen or halogen atom, and X denotes a nitrogen atom or CH--, from a heteroaromatic nitrile of the formulae III or IV, respectively: ##STR2## First, a microorganism, Alcaligenes faecalis (DSM 6335), is cultured in the presence of an inducer, 2-cyanopyridine, and a carbon source such as a dicarboxylic acid, a tricarboxylic acid or a carbohydrate. Substrate III or IV is then reacted with the cultured microorganism. The biotransformation is carried out under anaerobic conditions for compounds of the formula I, and under aerobic conditions for compounds of the formula II.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: December 30, 1997
    Assignee: Lonza, Ltd.
    Inventors: Andreas Kiener, Jean-Paul Roduit, Rainer Glockler
  • Patent number: 5700681
    Abstract: A method for selecting cell lines expressing increased cell adhesion properties or promoting cell differentiation by culturing cells in increasing concentrations of adhesion ligand containing media. Cell lines produced by such method.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: December 23, 1997
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Michael D. Pierschbacher, Erkki I. Ruoslahti, Shoukat Dedhar
  • Patent number: 5698429
    Abstract: Bacteria which produce large amounts of cellulase-containing cell-free fermentate have been identified. The original bacterium (ATCC 55703) was genetically altered using nitrosoguanidine (MNNG) treatment to produce the enhanced cellulase producing bacterium (ATCC 55702), which was identified through replicate plating. ATCC 55702 has improved characteristics and qualities for the degradation of cellulosic waste materials for fuel production, food processing, textile processing, and other industrial applications. ATCC 55702 is an improved bacterial host for genetic manipulations using recombinant DNA techniques, and is less likely to destroy genetic manipulations using standard mutagenesis techniques.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: December 16, 1997
    Assignee: Lockheed Martin Energy Systems, Inc.
    Inventor: H. Craig Dees
  • Patent number: 5695750
    Abstract: A method of detoxifying organophosphates using mutant cholinesterase which esists aging. The addition of oximes to the cholinesterase further retards aging of the cholinesterase.
    Type: Grant
    Filed: November 25, 1994
    Date of Patent: December 9, 1997
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Bhupandra P. Doctor, Donald Maxwell, Ashima Saxena, Zoran Radic, Palmer Taylor
  • Patent number: 5683689
    Abstract: The subject invention concerns novel biopesticides and their use to control cockroaches, carpenter ants, and pharaoh ants. Specifically, highly virulent isolates of Beauveria bassiana in an agricultural composition, can be used to effectively control these pests. Exemplified are Beauveria bassiana No. 447, ATCC 20872, and Beauveria bassiana SP111, ATCC 74038. Also described are unique formulations which are highly effective for delivering biocontrol agents to target pests. By using these novel compositions, target pests can be controlled without the environmental and public safety hazards presented by chemical control agents.
    Type: Grant
    Filed: March 21, 1994
    Date of Patent: November 4, 1997
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Jerry L. Stimac, Roberto Pereira
  • Patent number: 5677160
    Abstract: An improved fat splitting process which eliminates the induction period encountered during pressure splitting. A partial hydrolysis is conducted prior to pressure splitting by combining a lipase in the presence of water with the fat or oil to be hydrolyzed with added agitation. Pressure splitting of this partially split triglyceride eliminates or reduces the induction period.
    Type: Grant
    Filed: December 14, 1994
    Date of Patent: October 14, 1997
    Assignee: Henkel Corporation
    Inventors: Dean A. Oester, Allen L. Hall, Karl T. Zilch, Kevin W. Anderson
  • Patent number: 5676974
    Abstract: Pharmaceutical compositions for treatment of humans suffering from the symptoms of acquired immune deficiency syndrome (AIDS) or its precursors, lymphadenopathy syndrome (LAS) or AIDS-related complex (ARC) or secondary diseases relating thereto and other immunodeficiency pathologies or tumors resulting exclusively from immune deficiency and others such as H.I.V. The compositions contain a therapeutically active amount of phospholipase A.sub.2 and giroxina, preferably where the phospholipase A.sub.2 is isolated from the venom of Crotalus durissus terrificus or form the venom of Micrurus frontalis altirostris and the giroxina is isolated from the venom of Crotalus durissus terrificus. Also disclosed is the process for preparing such pharmaceutical composition and the process for treating patients suffering from the aforementioned afflictions.
    Type: Grant
    Filed: November 15, 1994
    Date of Patent: October 14, 1997
    Assignees: Santiago H. Valdes, Diego Jose Carpintero, Jorge Leandro Marini, Alejandro Ponieman
    Inventors: Santiago H. Valdes, Diego Jose Carpintero
  • Patent number: 5676944
    Abstract: The treatment of glaucoma and other conditions relating to diseased trabecular meshwork in the eye is effected by administration of macrophages and/or cytokines to the eye. Increased levels of macrophages within the anterior chamber of the eye will at least partially clear obstruction of the trabecular meshwork and restore viability of trabecular cells in order to enhance release of aqueous fluid from the anterior chamber and reduce intraocular pressures. The administration of cytolines will either recruit macrophages or will effect repair of the trabecular meshwork cells directly.
    Type: Grant
    Filed: October 6, 1993
    Date of Patent: October 14, 1997
    Assignee: The Regents of the University of California
    Inventors: Jorge A. Alvarado, Collin G. Murphy, Johnnie L. Hu
  • Patent number: 5677162
    Abstract: The present invention provides a method for activating prothrombin to thrombin in a prothrombin complex composition comprising at least prothrombin, Factors V, VII, IX, and X, and phospholipid, comprising the steps of: (a) cold-incubating the prothrombin complex composition with 2-15 mM of Ca.sup.2+ ions at a pH of 6.5-8.0 and at a temperature of 2.degree.-8.degree. C. until Factor VII contained in the composition is activated; and (b) incubating the cold-incubated composition at a pH of 6.5-8.0 and at a temperature of 10.degree.-25.degree. C. for a period of time sufficient to activate prothrombin contained in the composition to thrombin.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: October 14, 1997
    Assignee: New York Blood Center, Inc.
    Inventors: Jinsheng Zou, John Hamman, Gerard Marx, Bernard Horowitz
  • Patent number: 5674714
    Abstract: A process for inducing cytochrome P-450 enzyme production in bacteria of the genus Streptomyces using inducers such as soybean flour, genistein or genistin is described. Uses for the cytochrome P-450 enzymes produced are also discussed as is a process for using genetically engineered Streptomyces to determine the mutagenicity of chemicals.
    Type: Grant
    Filed: November 13, 1992
    Date of Patent: October 7, 1997
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: Daniel Anthony Kunz, Sima Fateme Sariaslani
  • Patent number: 5674715
    Abstract: A method for producing uridine diphosphate N-acetylglucosamine comprising culturing osmo-tolerant yeasts in aerobic conditions in a medium having inorganic salt concentration of about 2-8%.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: October 7, 1997
    Assignee: Tomita Pharmaceutical Co., Ltd.
    Inventors: Minoru Tomita, Hisao Mukai
  • Patent number: 5670173
    Abstract: The present invention relates to the production of a biocompatible and biodegradable polymer membrane comprising the steps of: a) mixing a polymer selected from the group consisting of polylactic acid, polyglycolic acid and polylactide-co-glycolide with a pharmaceutically acceptable surfactant; b) emulsifying an hemoglobin solution in the mixed solution of step a) to form particles of polymer membrane containing hemoglobin; c) solidifying the particles of step b) by adding cyclohexane; d) separating the solidified particles of step c) by centrifugation; and e) suspending the particles of step d) in a saline solution. In addition another approach uses alcohol-acetone. The biocompatible and biodegradable polymer membrane in accordance with the present invention contains from about 25 to 35% by weight of hemoglobin and has an average diameter from about 0.07 to 1.1.mu., preferably a submicron diameter of less than 0.2.mu..
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 23, 1997
    Assignee: McGill University
    Inventors: Thomas Ming Swi Chang, Wei-Ping Yu
  • Patent number: 5665598
    Abstract: A method is described for synthesis of N-Boc-L-propargylglycine, a key intermediate used in the preparation of high-potency, orally-active renin inhibitors. This method involves reaction of an organic halide with a glycine cation equivalent, such as methyl N-Boc-2-acetoxyglycine, in the presence of zinc dust to give Boc-protected amino acid derivatives in high yield. Typically useful organic halides are allylic, benzylic and propargylic halides. Resolution of methyl N-Boc-propargylglycine with .alpha.-chymotrypsin provides N-Boc-L-propargylglycine in high yield.
    Type: Grant
    Filed: January 29, 1996
    Date of Patent: September 9, 1997
    Assignee: G. D. Searle & Co.
    Inventors: Norman A. Abood, Roger A. Nosal
  • Patent number: 5665574
    Abstract: A method for preparing N-acetylneuraminic acid characterized in reacting N-acetylglucosamine with pyruvic acid in an alkaline condition by the action of N-acetylneuraminic acid lyase.
    Type: Grant
    Filed: September 14, 1995
    Date of Patent: September 9, 1997
    Assignee: Marukin Shoyu Co., Ltd.
    Inventors: Yoji Tsukada, Yasuhiro Ohta
  • Patent number: 5662900
    Abstract: A composition containing powdered Lactobacillus brevis subsp. coagulans is used to enhance the immunological functions of a patient, particularly with respect to increasing interferon production, 2-5A synthetase activity and Natural Killer activity.
    Type: Grant
    Filed: June 19, 1996
    Date of Patent: September 2, 1997
    Assignees: Institut Pasteur De Kyoto, Shinwa Pharmaceutical Co., Ltd., Nitto Pharmaceutical Industries, Ltd.
    Inventor: Tsunataro Kishida
  • Patent number: 5661034
    Abstract: Provided are serum-free media for tissue culture containing tissue inhibitor of metalloproteinases and methods for culturing animal cells using these media.
    Type: Grant
    Filed: November 16, 1994
    Date of Patent: August 26, 1997
    Assignee: Fuji Yakuhin Kogyo Kabushiki Kaisha
    Inventors: Taro Hayakawa, Kyoko Yamashita, Kazushi Iwata
  • Patent number: 5658793
    Abstract: Bacterial strains are capable of the formation of rhamnolipids, which they generate in the culture solution. If bacteria of the type Pseudomonas aeruginosa are employed for the fermentation, these microorganisms synthesize rhamnolipids in a concentration of 70-120 g/l of culture solution. The L-rhamnose can be recovered directly from the culture solution by hydrolysis of the rhamnolipids, i.e. without a complicated separation of the cell material and without isolation of the rhamnolipids before hydrolysis.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 19, 1997
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Carlo Giani, Dieter Wullbrandt, Reinhardt Rothert, Johannes Meiwes
  • Patent number: 5658789
    Abstract: A method for growing epithelial cells in vitro using soluble proteins secreted by 804G and NBT-II rat bladder carcinoma cells. These proteins stimulate cell attachment and hemidesmosome formation in cells grown in contact with the proteins. The protein is purified from conditioned medium by immunoaffinity chromatography using a monoclonal antibody generated against the protein. The purification of these proteins may be facilitated by culturing the cells under low serum or serum free conditions.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: August 19, 1997
    Assignee: Desmos, Inc.
    Inventors: Vito Quaranta, Marketta Hormia